Individual Macular Layer Evaluation with Spectral Domain Optical Coherence Tomography in Normal and Glaucomatous Eyes.
glaucoma
macula
optic nerve
optical coherence tomography
visual field
Journal
Clinical ophthalmology (Auckland, N.Z.)
ISSN: 1177-5467
Titre abrégé: Clin Ophthalmol
Pays: New Zealand
ID NLM: 101321512
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
04
2020
accepted:
20
05
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
2
7
2020
Statut:
epublish
Résumé
To evaluate differences in the thickness of the individual macular layers between early, moderate, and severe glaucomatous eyes and compare them with healthy controls. Subjects with glaucoma presenting typical optic nerve head findings, high intraocular pressure with or without visual field (VF) damage and normal controls were included. All participants underwent 24-2 perimetry and spectral-domain OCT. Patients were divided into three groups (early, moderate, and severe) based on the mean deviation of the VF and a healthy control group. The device segmented the layers automatically, and their measurements were plotted using the means of the sectors of the inner (3mm) and outer (6mm) circles of the ETDRS grid. A total of 109 eyes qualified for the study: 14 in the control group and 52, 18 and 25 in the early, moderate and severe groups, respectively. Mean age was 66.13 (SD=12.38). The mean thickness of the circumpapillary retinal nerve fiber layer (RNFL), total macular thickness (TMT), macular RNFL, ganglion cell layer (GCL) and inner plexiform layer (IPL) were significantly different between the 4 groups, with progressive decrease in thickness. Significant overall difference was found for the inner nuclear layer (INL), and the severe glaucoma group presented thicker measurements than controls and early glaucoma. Outer nuclear layer (ONL) was thinner in severe glaucoma group compared with early glaucoma group. Individual macular layer measurement using the inner and outer circles of the ETDRS grid is useful to evaluate different stages of glaucoma. The INL thickening and ONL thinning in advanced glaucoma should be explored in the future studies.
Identifiants
pubmed: 32606574
doi: 10.2147/OPTH.S256755
pii: 256755
pmc: PMC7304678
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1591-1599Informations de copyright
© 2020 Fujihara et al.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Invest Ophthalmol Vis Sci. 2011 Feb 16;52(2):940-6
pubmed: 20881293
J Ophthalmol. 2011;2011:264803
pubmed: 21845213
Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4646-51
pubmed: 20435603
Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2242-50
pubmed: 10476789
Arch Ophthalmol. 2000 Feb;118(2):235-45
pubmed: 10676789
Ophthalmology. 2018 Dec;125(12):1907-1912
pubmed: 29934267
Ophthalmology. 1998 Feb;105(2):224-31
pubmed: 9479279
BMC Ophthalmol. 2019 Jan 8;19(1):12
pubmed: 30621639
Br J Ophthalmol. 2011 Jan;95(1):131-41
pubmed: 20956277
J Neuroophthalmol. 2007 Sep;27(3):176-9
pubmed: 17895816
Brain. 2012 Dec;135(Pt 12):e226; author reply e227
pubmed: 23078994
Lancet. 2011 Apr 16;377(9774):1367-77
pubmed: 21453963
Ophthalmology. 2017 Oct;124(10):1466-1474
pubmed: 28549518
Invest Ophthalmol Vis Sci. 1995 Jan;36(1):200-5
pubmed: 7822147
Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5681-90
pubmed: 26313303
Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1446-52
pubmed: 19834029
Br J Ophthalmol. 2012 Dec;96(12):1452-5
pubmed: 23018425
Surv Ophthalmol. 2008 Nov;53 Suppl1:S17-32
pubmed: 19038620
Am J Ophthalmol. 2017 Mar;175:37-44
pubmed: 27914978
Invest Ophthalmol Vis Sci. 2013 Jul 01;54(7):4422-9
pubmed: 23722389
Acta Ophthalmol (Copenh). 1984 Aug;62(4):658-64
pubmed: 6485761
Brain. 2013 Jul;136(Pt 7):e239
pubmed: 23396580
Surv Ophthalmol. 2014 Jul-Aug;59(4):458-67
pubmed: 24388709
Jpn J Ophthalmol. 2007 May-Jun;51(3):197-203
pubmed: 17554482
Prog Retin Eye Res. 2013 Jan;32:1-21
pubmed: 22995953
PLoS One. 2015 Jun 12;10(6):e0130175
pubmed: 26066021
Ophthalmology. 2005 Mar;112(3):391-400
pubmed: 15745764
Graefes Arch Clin Exp Ophthalmol. 1992;230(6):505-10
pubmed: 1427131
Curr Opin Ophthalmol. 2014 Mar;25(2):104-11
pubmed: 24370973
Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4799-4805
pubmed: 27654408
Ophthalmology. 2017 Aug;124(8):1218-1228
pubmed: 28461015
Ophthalmology. 2003 Jan;110(1):177-89
pubmed: 12511364
Science. 1991 Nov 22;254(5035):1178-81
pubmed: 1957169
Curr Opin Ophthalmol. 1995 Apr;6(2):89-95
pubmed: 10150863
Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5685-9
pubmed: 20538998
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT511-8
pubmed: 27454660
Eye (Lond). 2011 Mar;25(3):279-89
pubmed: 21293495
Invest Ophthalmol. 1969 Feb;8(1):84-91
pubmed: 5763849
Br J Ophthalmol. 2006 Mar;90(3):262-7
pubmed: 16488940
PLoS One. 2018 Dec 31;13(12):e0209610
pubmed: 30596720
J Glaucoma. 2011 Apr-May;20(4):252-9
pubmed: 20520570
Brain. 2012 Dec;135(Pt 12):e225
pubmed: 22960546
Br J Ophthalmol. 2015 Jun;99(6):732-7
pubmed: 25492547
Br J Ophthalmol. 2012 May;96(5):614-8
pubmed: 22133988
PLoS One. 2015 May 15;10(5):e0125957
pubmed: 25978420
PLoS One. 2013 Aug 06;8(8):e71145
pubmed: 23940706
Am J Ophthalmol. 1995 Aug;120(2):184-9
pubmed: 7639302
Am J Ophthalmol. 2004 Aug;138(2):218-25
pubmed: 15289130
Lancet Neurol. 2012 Nov;11(11):963-72
pubmed: 23041237
Br J Ophthalmol. 2012 Nov;96(11):1420-5
pubmed: 22914498
Ophthalmology. 2012 Jun;119(6):1151-8
pubmed: 22365056
JAMA Ophthalmol. 2014 Mar;132(3):291-7
pubmed: 24407153
Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2012-7
pubmed: 15914617
Brain. 2013 Nov;136(Pt 11):e260
pubmed: 23872368
Surv Ophthalmol. 2016 Sep-Oct;61(5):597-615
pubmed: 27018149
PLoS One. 2018 Jan 4;13(1):e0190621
pubmed: 29300765
Curr Opin Ophthalmol. 2013 Mar;24(2):150-61
pubmed: 23328662
Am J Ophthalmol. 2005 Jan;139(1):44-55
pubmed: 15652827
JAMA Neurol. 2013 May;70(5):629-33
pubmed: 23529376
J Glaucoma. 2010 Oct-Nov;19(8):528-34
pubmed: 20164794